Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy using neoantigen-targeted peripheral cells for ATLAS identified anti-tumor antigens that are used to manufacture peripheral blood-derived tumor-specific T cell therapy; and GEN-009, a neoantigen vaccine candidate, delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.
IPO Year: 2014
Exchange: NASDAQ
Website: genocea.com
SVB Leerink reiterated coverage of Genocea Biosciences with a rating of Outperform and set a new price target of $6.00 from $5.00 previously
Needham reiterated coverage of Genocea Biosciences with a rating of Buy and set a new price target of $6.00 from $7.00 previously
15-12B - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
EFFECT - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
EFFECT - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
POS AM - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
POS AM - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
EFFECT - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
EFFECT - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
POS AM - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
POS AM - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
25 - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)